AN9025, an oral small molecule pan-RAS(ON) inhibitor with best-in-class potential, is being evaluated in a global Phase I clinical trial in patients with advanced or metastatic solid tumors harboring RAS mutations. The first patient was dosed in the once-daily (QD) arm in February 2026, and the first patient was dosed in the intermittent once-weekly (QW) arm in July 2026. The Company remains on track to share initial Phase Ia dose escalation data from the QD arm in the first half of 2027, with a potential early look at the QW arm.

AN9025 demonstrates superior potency compared to a clinical benchmark pan-RAS(ON) inhibitor sharing the same mechanism of action, driving potent and broad-spectrum anti-tumor activity in both in vitro and in vivo models.

AN9025 inhibits the viability of RAS-addicted cancer cell lines

Antitumor effects of AN9025 in KRAS-driven xenograft mice models

AN9025 exhibited a therapeutic index comparable to or slightly superior to that of RMC-6236 in a QD regimen, despite its significantly greater potency.

Reference

1. AN9025, an orally bioavailable pan-RAS(ON) inhibitor with potent, broad-spectrum anti-tumor activity, AACR 2025